What is the guideline‑directed medical therapy for a typical adult with heart failure with reduced ejection fraction?

Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction

All adults with HFrEF (LVEF ≤40%) should receive simultaneous initiation of four foundational medication classes—ARNI (or ACE-I/ARB), evidence-based beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor—at low doses within the first 2–4 weeks after diagnosis, then uptitrated every 1–2 weeks to target doses, which reduces 2-year mortality by approximately 73% compared to no disease-modifying therapy. 1, 2

The Four Pillars of GDMT

1. Renin-Angiotensin System Inhibition

• Sacubitril/valsartan (ARNI) is the preferred first-line agent, providing at least 20% mortality reduction superior to ACE inhibitors (which provide only 5–16% reduction) and ARBs. 1, 2

• Start sacubitril/valsartan at 49/51 mg twice daily and uptitrate to target dose of 97/103 mg twice daily over 4–8 weeks. 1, 2

• If ARNI is not tolerated or available, use an ACE inhibitor (e.g., enalapril 2.5 mg twice daily → target 10–20 mg twice daily; lisinopril 2.5–5 mg daily → target 20–35 mg daily) or ARB (e.g., losartan 50 mg daily → target 150 mg daily; valsartan 40 mg twice daily → target 160 mg twice daily). 1, 2

• Critical safety rule: Observe a strict 36-hour washout period when switching from ACE inhibitor to ARNI to avoid angioedema. 2

2. Evidence-Based Beta-Blockers

• Only three beta-blockers have proven mortality benefit in HFrEF: carvedilol, metoprolol succinate (extended-release), and bisoprolol—each providing at least 20% mortality reduction and decreased sudden cardiac death. 1, 2

• Dosing protocols:

  • Carvedilol: start 3.125 mg twice daily → target 25–50 mg twice daily
  • Metoprolol succinate: start 12.5–25 mg daily → target 200 mg daily
  • Bisoprolol: start 1.25 mg daily → target 10 mg daily 1, 2

• Do not use metoprolol tartrate (immediate-release), as it has never demonstrated mortality benefit in HFrEF; only metoprolol succinate is guideline-recommended. 1

• Initiate beta-blockers after volume optimization and discontinuation of IV diuretics, vasodilators, and inotropes in hemodynamically stable patients. 2

3. Mineralocorticoid Receptor Antagonists (MRAs)

• Spironolactone or eplerenone each provide at least 20% mortality reduction and lower sudden cardiac death risk. 1, 2

• Start spironolactone 12.5–25 mg daily → target 50 mg daily, or eplerenone 25 mg daily → target 50 mg daily. 1, 2

• If gynecomastia develops with spironolactone (occurs in ~10% of men), switch to eplerenone. 1

• Requires monitoring of potassium and creatinine; can be used if eGFR >30 mL/min/1.73 m². 1

4. SGLT2 Inhibitors

• Dapagliflozin 10 mg daily or empagliflozin 10 mg daily provide significant mortality benefit regardless of diabetes status, with clinical improvement occurring within weeks. 1, 2

• No dose titration required—start at full therapeutic dose. 1, 2

• Minimal blood pressure, heart rate, or potassium effects, making them ideal first agents in patients with borderline BP. 1

• Can be used if eGFR ≥30 mL/min/1.73 m² for empagliflozin or ≥20 mL/min/1.73 m² for dapagliflozin. 1

Simultaneous Initiation Strategy

• Start all four medication classes at low doses simultaneously or within the first 2–4 weeks, rather than waiting to achieve target dosing of one before initiating the next. 1, 2

• This approach addresses the massive treatment gap where less than 25% of eligible patients receive all four agents concurrently and only 1% achieve target doses of all medications. 1, 2

• Uptitrate one drug at a time every 1–2 weeks using small increments until target or maximally tolerated dose is achieved. 1

• Prioritize SGLT2 inhibitor and MRA first during uptitration since they have minimal blood pressure effects, then beta-blocker, then ARNI. 1

Loop Diuretics for Volume Management

• Loop diuretics are essential for congestion control but do not reduce mortality—they provide symptom relief only. 1, 2

• Dosing:

  • Furosemide: start 20–40 mg once or twice daily → maximum 240 mg daily
  • Torsemide: start 10–20 mg daily → maximum 200 mg daily
  • Bumetanide: start 0.5–1.0 mg once or twice daily → maximum 10 mg daily 1

• Titrate diuretic dose to achieve euvolemia (no edema, no orthopnea, no jugular venous distension), then use the lowest dose that maintains this state. 1

Managing Low Blood Pressure During Optimization

• Never discontinue or down-titrate GDMT for asymptomatic hypotension with adequate perfusion—patients can safely tolerate systolic BP 80–100 mmHg if organ perfusion is adequate. 1, 2

• GDMT medications maintain efficacy and safety even in patients with baseline SBP <110 mmHg. 1

• If SBP is around 90 mmHg at baseline:

  • Start SGLT2 inhibitor and MRA first (minimal BP effects)
  • Add beta-blocker only if resting heart rate >60 bpm
  • Then add low-dose ARNI/ACE-I/ARB 1

• For symptomatic hypotension (SBP <80 mmHg or major symptoms):

  • First, address reversible non-HF causes: stop alpha-blockers (e.g., tamsulosin), discontinue other non-essential BP-lowering medications, evaluate for dehydration/infection/acute illness
  • Second, implement non-pharmacological interventions: compression leg stockings for orthostatic symptoms, exercise training programs, adequate salt and fluid intake if not volume overloaded
  • Third, if symptoms persist: reduce ARNI/ACE-I/ARB dose first if heart rate >70 bpm, or reduce beta-blocker dose first if heart rate <60 bpm
  • Always maintain SGLT2 inhibitor and MRA (minimal BP effects) 1

Monitoring Requirements

• Check blood pressure, heart rate, renal function, and electrolytes 1–2 weeks after each dose increment, with more frequent monitoring in elderly patients and those with chronic kidney disease. 1, 2

• Modest increases in creatinine (up to 30% above baseline) are acceptable and should not prompt discontinuation of ARNI/ACE-I/ARB. 1

• Potassium levels require close monitoring with MRAs; if hyperkalemia develops, consider potassium binders (e.g., patiromer) rather than discontinuing life-saving medications. 1

• Schedule early follow-up within 7–14 days after medication adjustments to evaluate volume status, blood pressure, renal function, and electrolytes. 1, 2

Additional Therapies for Specific Subgroups

Ivabradine

• Add ivabradine only if: patient is in sinus rhythm with NYHA class II–III symptoms, resting heart rate ≥70 bpm despite maximally tolerated beta-blocker dose. 1, 2
• Start 5 mg twice daily → target 7.5 mg twice daily. 1

Hydralazine/Isosorbide Dinitrate

• For self-identified Black patients with NYHA class III–IV symptoms despite optimal quadruple therapy, add hydralazine 25 mg three times daily + isosorbide dinitrate 20 mg three times daily. 1, 2

Critical Contraindications and Medications to Avoid

• Never combine ACE inhibitor with ARNI due to angioedema risk. 1, 2

• Never use triple combination of ACE inhibitor + ARB + MRA due to extreme hyperkalemia and renal dysfunction risk. 1, 2

• Avoid diltiazem or verapamil in HFrEF—they increase the risk of worsening heart failure and hospitalization. 1, 2

• Do not use non-evidence-based beta-blockers (e.g., atenolol, labetalol)—only carvedilol, metoprolol succinate, and bisoprolol have proven mortality benefit. 1

Common Pitfalls to Avoid

• Delaying initiation of all four medication classes—start simultaneously within 2–4 weeks of diagnosis. 1, 2

• Accepting suboptimal doses without aggressive uptitration—clinical trials demonstrated benefits at target doses, not low doses. 1

• Stopping medications for asymptomatic hypotension—adverse events occur in 75–85% of HFrEF patients regardless of treatment, with no substantial difference between GDMT and placebo arms. 1

• Inadequate monitoring—check labs 1–2 weeks after each dose change to detect and manage adverse effects early. 1

• Premature discontinuation for temporary symptoms—fatigue and weakness with dose increases usually resolve within days. 2

• Overreacting to laboratory changes—modest creatinine elevation (up to 30% above baseline) is acceptable. 2

Device Therapy Considerations

• Implantable cardioverter-defibrillator (ICD) is indicated for primary prevention in patients with symptomatic HF (NYHA Class II–III) and LVEF ≤35% despite ≥3 months of optimal medical therapy, who are expected to survive >1 year with good functional status. 1

• Cardiac resynchronization therapy (CRT) is recommended for symptomatic HFrEF patients in sinus rhythm with QRS duration ≥150 msec and left bundle branch block (LBBB) morphology with LVEF ≤35% despite optimal medical therapy. 1

Expected Outcomes

• Combined quadruple therapy provides approximately 5.3 additional life-years compared to no treatment and roughly 6 additional life-years versus traditional dual therapy (ACE-I and beta-blocker). 1, 2

• All-cause mortality is reduced by 61% (HR 0.39,95% CI 0.32–0.49) with full quadruple therapy at target doses. 1, 2